uniQure Signs 53,343 SF Lease for Pharmaceutical Manufacturing Facility in Lexington

-Dutch-based world leader in human based gene therapies to build production facility in Greater Boston

Cushman & Wakefield today announced the completion of a 53,343 square foot office, laboratory and GMP manufacturing lease at 113 Hartwell Avenue in Lexington. Cushman & Wakefield Executive Directors Mark Winters and Richard Ruggiero represented the tenant, uniQure, in the transaction. The landlord is King Street Properties LLC.

“We are delighted to further expand uniQure’s operations with the opening of a world-class facility in the Boston area, which is one of the world’s leading destinations for life science entities”, said Jörn Aldag, CEO of uniQure. “The construction of this facility represents our commitment to establishing a global, fully integrated gene therapy company as we continue to build on our leadership position in the field of AAV-based gene therapy products.

Stephen Lynch, Principal of King Street Properties LLC, added: “The announcement that uniQure, a world leader in the life science industry, has selected Lexington for its regional base of operations speaks volumes about the quality and location of our facility. We look forward to supporting uniQure’s presence in this market.”

uniQure’s 10-year lease at 113 Hartwell Avenue will enable the firm to establish a state of the art production facility in the US which may eventually employ over 50 professionals. The building is currently undergoing extensive base building and architectural improvements designed to transform the existing 103,000 square foot building into a state-of-the-art life science facility.

Based in Amersterdam, the Netherlands, uniQure’s lead product, Glybera, was developed for the treatment of lipoprotein lipase deficiency was approved by the European Commission in November 2012. Glybera is the first gene therapy approved in the Western world. uniQure has a product pipeline with several gene therapies: for hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo B. The company employs a staff with extensive scientific and industry experience, and is the world leader in manufacturing of AAV-based products on a commercial scale and has extensive experience in the regulatory process for gene therapies.